4 hours ago
2
Key Takeaways
- Moderna shares plummeted 10.7% on July 10, 2026, shedding $8.17 to settle at $68.39
- Company insiders offloaded $6.2 million in shares over three months with no insider purchases reported
- First quarter earnings per share landed at -$3.40, falling short of the -$3.02 forecast, while revenue hit $389M versus expected $236.37M
- Analyst consensus leans toward “Reduce” with an average price target of just $38.27
- QRG Capital Management initiated a fresh stake, acquiring 13,666 shares valued at approximately $694,000
Shares of Moderna experienced a brutal selloff on July 10, 2026, plunging 10.7% in a single session — an $8.17 decline — to finish at $68.39. This sharp downturn reflects mounting challenges facing the biotech firm.
Trading commenced that morning at $76.56. The stock’s 52-week trading range spans from a low of $22.28 to a peak of $85.60, positioning the current valuation in the upper portion of that spectrum — though the recent tumble indicates potential downward momentum.
The latest quarterly results, unveiled on May 1, failed to inspire confidence. Moderna recorded a per-share loss of $3.40, exceeding the anticipated -$3.02 deficit. Such misses typically leave lasting impressions on investor sentiment.
On the revenue front, performance told a contrasting tale. The biotech company generated $389 million during the quarter, substantially surpassing the $236.37 million Wall Street projection. This represents a dramatic 260.2% year-over-year surge.
However, impressive top-line growth offers limited comfort when bottom-line challenges persist. The company continues to grapple with a deeply negative net margin of 143.55% alongside a concerning negative return on equity of 26.64%.
Executive Stock Disposals Raise Red Flags
Corporate insiders have been steadily reducing their holdings. Throughout the previous three months, they disposed of $6.2 million in equity — with absolutely zero purchases to offset the selling.
Board member Noubar Afeyan liquidated 9,263 shares on May 21 at $46.84 apiece, slashing his stake by a substantial 70.24%. Meanwhile, President Stephen Hoge unloaded 53,336 shares on June 15 at $51.37 each, generating proceeds of approximately $2.74 million.
While these transactions occurred through predetermined 10b5-1 trading arrangements, the significant selling activity invariably raises eyebrows among market participants.
Company insiders maintain ownership of 10.80% of outstanding shares. Institutional stakeholders control 75.33%.
Analyst Community Maintains Skeptical Stance
The Wall Street research community’s outlook remains decidedly lukewarm. Among 18 analysts tracking Moderna, just two recommend buying, eleven advise holding, and five suggest selling. The composite rating translates to “Reduce.”
The mean price objective stands at $38.27 — substantially beneath current trading levels.
Morgan Stanley recently adjusted its target upward from $33 to $39 while maintaining an “equal weight” stance. Goldman Sachs lifted its forecast from $43 to $49 with a “neutral” designation. Bank of America increased its target from $34 to $38 yet retained an “underperform” classification.
Weiss Ratings sustained a “sell (d-)” recommendation on June 12.
Regarding institutional activity, QRG Capital Management established a new holding during the first quarter, accumulating 13,666 shares representing roughly $694,000 in value. Several other smaller investment firms also initiated positions, though the investments remained relatively minor.
Moderna’s GF Score registers at 58 out of a possible 100. Financial Strength scores 7/10, Growth scores 7/10, yet Profitability manages only 3/10.
The 50-day moving average currently sits at $55.75. The 200-day moving average rests at $49.53. Sell-side analysts collectively project full-year earnings per share of -$6.51.
The post Moderna (MRNA) Stock Plunges Over 10% Amid Insider Sales and Bearish Analyst Sentiment appeared first on Blockonomi.
English (US) ·